In this manuscript, we report that the inhibition of CRM1 by S109 might significantly promote the nuclear retention of Foxo1, and our results indicate that redirecting Foxo1 to the nucleus by inhibiting CRM1 might be an effective approach for treating gliomas. Here, FOXO1 is linked to glioma.